Geneva/New York/Oslo: COVAX has called on regional, national and local government authorities to recognize as fully vaccinated all people who have been vaccinated with COVID-19...
INDIA: India achieved another milestone after surpassing the US in the administration of COVID-19 vaccine doses on Sunday. According to the Union Health Ministry,...
THAILAND. Bangkok: The Tourism Authority of Thailand (TAT), in partnership with the King Power International Group, has launched a new marketing campaign, “Phuket is...
NIGERIA: More countries would be able to access more vaccines as the World Health Organization (WHO) has validated the Sinovac-CoronaVac COVID-19 vaccine for emergency...
Brazzaville: Africa urgently needs at least 20 million doses of the Oxford-AstraZeneca vaccine in the next six weeks.
This would enable the Continent to give...
NIGERIA: The World Health Organization (WHO) Regional Director for Africa, Dr Matshidiso Moeti has said that 24 million Africans have received at least one...
EUROPEAN UNION: European Union n Wednesday announced to ease COVID-19 travel restrictions on non-EU visitors ahead of the summer tourist season. Ambassadors from the...
The first batch of Russian COVID-19 vaccine- “Sputnik V”, developed by Russia’s Gamaleya National Center Covid, has arrived and more batches will be arriving and the vaccine is likely to be available in the market by next week, Dr. VK Paul, Member-Health of Niti Aayog said on Thursday.
NIGERIA: 1,289,773 Nigerians have been vaccinated with the first dose of the COVID-19 vaccine across Nigeria as of May 6th.
This makes 64.1 per cent...
UNITED KINGDOM: On 24th April 2021, people from all walks of life marched peacefully in London against lockdowns and Vaccine Passports.
Read also: The Portuguese...
US health officials are warning doctors that heparin, a common treatment for blood clots, can worsen the vaccine-linked condition.
Photo Credit: Twitter
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkNoPrivacy policy
